公司资料
Dynavax Technologies 股价、新闻与催化剂
已退市
- 股票代码:
- DVAX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
目前无法获取 DVAX 的收盘价变动背景。
公司概览
业务概览
Dynavax Technologies is a vaccine company best known for HEPLISAV-B and additional innate-immune platform work. The company combines commercial product execution with immunology-driven pipeline optionality.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Dynavax sits in specialty biopharma.
商业模式特征
The business depends on vaccine sales, commercial traction, and the ability to expand beyond its core hepatitis-B franchise.
生物医药行业定位
Dynavax is a commercial specialty-pharma name with catalyst sensitivity around vaccines, partnerships, and pipeline progress.
未来催化剂
- Dynavax's catalysts are HEPLISAV-B execution and CpG 1018 adjuvant partnerships, which together support the vaccine-platform story. The company improves when the commercial base and partner flow both stay healthy.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。